Nanoparticle albumin-bound paclitaxel and nivolumab for PD-1 inhibitor-refractory recurrent or metastatic head and neck squamous-cell carcinoma

Authors

• Douglas Adkins, Washington University School of Medicine in St. Louis
• Jessica C Ley, Washington University School of Medicine in St. Louis
• Christine Auberle, Washington University School of Medicine in St. Louis
• Brendan Knapp, Washington University School of Medicine in St. Louis
• Jesse Zaretsky, Washington University School of Medicine in St. Louis
• Jingxia Liu, Washington University School of Medicine in St. Louis
• Peter Oppelt, Washington University School of Medicine in St. Louis

Journal

Cancer Medicine

Publication Date

1-1-2026

Volume

15

Issue

1

First Page

e71533

Document Type

Open Access Publication

DOI

10.1002/cam4.71533

Rights and Permissions

D. Adkins, J. C. Ley, C. Auberle, et al., “ Nanoparticle Albumin-Bound Paclitaxel and Nivolumab for PD-1 Inhibitor-Refractory Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma,” Cancer Medicine 15, no. 1 (2026): e71533, https://doi.org/10.1002/cam4.71533. © 2026 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Recommended Citation

Adkins, Douglas; Ley, Jessica C; Auberle, Christine; Knapp, Brendan; Zaretsky, Jesse; Liu, Jingxia; and Oppelt, Peter, "Nanoparticle albumin-bound paclitaxel and nivolumab for PD-1 inhibitor-refractory recurrent or metastatic head and neck squamous-cell carcinoma." Cancer Medicine. 15, 1. e71533 (2026).
https://digitalcommons.wustl.edu/oa_4/7197

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.